CTT Competitive Technologies 40 Milliarden Jetzt macht es bummmmm - 500 Beiträge pro Seite

[aktienworker]

Source: Competitive Technologies, Inc.
Competitive Technologies' Pain Management Technology Delivers Dramatic New Results in Europe
CTT Commercialization Plan Moves Forward

FAIRFIELD, Conn., Dec. 19, 2007 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT) announced today that its European CE-certified pain management therapy device has been successfully used to treat pain related to herpes zoster, commonly known as shingles or zoster, in a pregnant woman in Italy. Developed by CTT's client, Prof. Giuseppe Marineo in Italy, and brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., CTT has exclusive worldwide rights to the therapy for a non-invasive method for rapid treatment of high-intensity oncologic, neuropathic and morphine-resistant pain through a biophysical rather than a biochemical approach. The pain management device allowed the woman, in her twenty-fifth week of pregnancy, to be successfully treated for her painful zoster outbreak in a manner that did not interfere with her condition or that of the fetus.

The non-invasive treatment has already been used with successful results in seven hospitals in Italy on over 2,000 patients suffering from intense drug-resistant pain. The treatment uses a multi-processor device designed to create self-like neurons by applying surface electrodes to the skin to simultaneously treat multiple pain areas.

The device has Medical Device CE certification from the European Union allowing European sales. Sales and distribution in Europe are expected to begin in a few months, by April 2008. The device will be manufactured by CTT licensee Daeyang E&C. Korea-based Daeyang is producing the device for worldwide distribution.

CTT also announced today that they signed an agreement with Medical Device Consultants, Inc. (MDCI) for MDCI to assist CTT in obtaining U.S. FDA 510(k) approval to market the pain management technology as a Class II device in the U.S. CTT is also taking steps to obtain regulatory approval for sales of the product in Korea.

"We fully expect revenue and profits from the pain management technology to dramatically exceed the financial results produced by any technology in CTT's 40-year history," said John B. Nano, CTT's Chairman, President and CEO. "When the phenomenal potential of this technology is fully recognized by the investment community, we anticipate a substantially favorable improvement in the market valuation of the company. The pain management market is estimated to reach $40 billion by 2010."

Mr. Nano continued, "This is an example of a CTT technology being at the forefront of the paradigm shift to treat individuals with integrative medicine, combining both traditional medicine and holistic medicine. Our strategy is to exploit the resulting dynamic opportunities by broadening our base of technologies that treat individuals with biophysical as well as biochemical methods. We believe this paradigm creates opportunities for new technologies for CTT to exploit. The pain management technology is an important part of our rapidly developing medical strategy."

Daeyang is investing about $1 million to design and tool the manufacturing of the device for worldwide distribution. CTT's agreement with Daeyang provides equally shared profits between CTT and Daeyang in a new CTT business model to increase profit margins.

Mr. Nano added, "CTT is focused on creating value from technologies, restoring stockholder value by signing new license agreements. We are aggressively marketing this pain management therapy, as well as our MC Square stress reduction device (www.relaxmc.com), solar panels, UAD tubular-connection, LED patents and Radio Alert Warning System technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2006, filed with the SEC on October 30, 2006, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

CONTACT: IR Services, LLC
Johnnie D. Johnson
860 434 2465
[e-mail]

[aktienworker]

und der Laden ist nur mit Euro 9 Mill.bewertet

[Datteljongleur]

Antwort auf Beitrag Nr.: 32.820.937 von aktienworker am 19.12.07 22:48:47

Na dann les dir mal dieses SEC-filling genau durch:

http://biz.yahoo.com/e/071214/ctt10-q.html

[aktienworker]

Antwort auf Beitrag Nr.: 32.824.551 von Datteljongleur am 20.12.07 12:08:02

ups, mein Englisch reicht nicht, aber was ist denn an der Nachricht mit den 40 Mill.dran?
Vielleicht hat jemand ein genügendes Englisch.

[aktienworker]

plus 28 %

[lerchengrund]

Competitive Technologies Reports Second Quarter Fiscal 2008 Results
FAIRFIELD, Conn., March 17, 2008 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT) today announced financial results for the three and six months ended January 31, 2008.


The financial results for the second quarter ended January 31, 2008 are a net loss of approximately $1.3 million, or $0.16 per share, a 64% improvement when compared to the net loss of approximately $3.6 million, or $0.44 per share, for the prior year quarter. The net loss for the six-month period ending January 31, 2008 is $3.9 million, or $0.47 per share, a 17% improvement when compared to the net loss of $4.7 million, or $0.59 per share, for the prior-year period. Cash position at quarter end was $4.5 million, with no long-term debt.

"Although results are very disappointing, the decrease in net loss for both the current quarter and six-month periods compared to 2007 indicates that we are moving in the right direction toward restoring profitability," said John B. Nano, CTT's Chairman, President and CEO. "We reduced costs for the second quarter fiscal 2008 by 59% below the prior-year quarter. The benefit of our cost reduction program will continue in the third quarter fiscal 2008, where we expect operating costs to decline an additional 30% from the current quarter.

"We continue to build a technology portfolio that exploits the opportunities of the paradigm shift resulting from record high costs of both healthcare and energy. Sales prospects for our innovative pain management device, a significant component of our rapidly developing medical strategy, are highly encouraging. The non-invasive treatment, with European Union Medical Device CE certification, has been successfully used in seven hospitals in Italy on over 2,000 patients suffering from intense drug-resistant pain. The device is being manufactured by CTT licensee Daeyang E&C of Korea for worldwide distribution.

"Many factors contribute to CTT's improving picture. A 40% staff reduction has lowered operating costs. Arbitration with Palatin Technologies, Inc. has been settled, allowing CTT to reclaim its proper rights to the important sexual dysfunction technology. Expansion of our medical strategy includes a license to Percept BioSciences for development of a library of patented attention and cognitive enhancement compounds from our client, the Medical College of Georgia, and an agreement to represent Angioscan's non-invasive early-detection test for breast cancer. We have also signed an agreement to represent NTRU in Korea for their suite of products for embedded security software solutions."

Total revenues for the quarter ended January 31, 2008, were approximately $0.5 million, compared to approximately $0.9 million in the same period of the prior year. Revenues for the six-month period ended January 31, 2008 were $0.7 million compared to $1.8 million in the same period of the prior year. The decrease in total revenues was primarily due to the decrease in retained royalties for homocysteine, partially offset by increased royalties for the sexual dysfunction technology. CTT is currently pursuing litigation against alleged infringers of its homocysteine assay patent.

Expenses for the quarter ended January 31, 2008 were approximately $1.8 million, a 59% decrease, compared to approximately $4.5 million in the prior year quarter. Expenses for the six-month period ended January 31, 2008 were approximately $4.6 million, a 29% decrease, compared to $6.5 million for the prior year period.

The current quarter and six month periods, when compared to prior year periods, include cost reductions of $0.5 million from reduction of staff and related costs, approximately $0.6 million associated with the prior Board and management's annual meetings and proxy contest, $1.6 million settlement of an employee suit including related legal expenses, and about $0.5 million received from the Palatin arbitration settlement, reducing incurred patent enforcement costs. Offsetting the savings were increased legal fees, primarily related to the Marcovitch suit, of $0.2 million and $0.5 million in the current quarter and six months, respectively. A non-cash charge for impairment of available-for-sale-securities of $0.2 million was included in the current six months expenses.

Mr. Nano continued, "CTT's management team is focused on creating value from technologies, restoring shareholder value, building global alliances, and maximizing the dynamic opportunities of our technologies. We have broadened our portfolio with technologies that treat individuals with integrative medicine combining both traditional and holistic medicine, and strengthened our alternative energy portfolio segment. We are aggressively marketing the pain management therapy, breast cancer detection test, MC Square stress reduction device (www.relaxmc.com), solar panels, UAD surgical prosthetics, and the LED portfolio technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



COMPETITIVE TECHNOLOGIES, INC.

FIRST HALF FISCAL 2008

CONDENSED CONSOLIDATED RESULTS OF OPERATIONS
(dollars in thousands, except per share amounts) (unaudited)

Second Quarter Six Months
Ended January 31, Ended January 31,
2008 2007 2008 2007
---- ---- ---- ----


Revenue $ 530 $ 904 $ 730 $ 1,799

Operating expenses 1,829 4,467 4,589 6,484

Provision for income tax -- -- -- --
------- ------- ------- -------

Net (loss) $(1,299) $(3,563) $(3,859) $(4,685)
======= ======= ======= =======

Net (loss) per share:
Basic and diluted $ (0.16) $ (0.44) $ (0.47) $ (0.59)
======= ======= ======= =======


Weighted average number
of common shares
outstanding:
Basic and diluted (000) 8,159 8,017 8,133 8,003


At January 31, At July 31,
2008 2007
---- ----
Other Financial Data
Cash and cash equivalents $ 4,522 $ 6,572
=========== ===========
Total assets $ 5,762 $ 9,713
=========== ===========

Total liabilities $ 2,161 $ 2,114
=========== ===========

Shareholders' equity $ 3,601 $ 7,599
=========== ===========

CONTACT: IR Services, LLC
Johnnie D. Johnson,
CT - 860 434 2465
NY - 212 848-0275
[e-mail]


--------------------------------------------------------------------------------

[lerchengrund]

COMPETITIVE TECHNOLOGIES, INC.

FIRST HALF FISCAL 2008

CONDENSED CONSOLIDATED RESULTS OF OPERATIONS
(dollars in thousands, except per share amounts) (unaudited)

Second Quarter Six Months
Ended January 31, Ended January 31,
2008 2007 2008 2007
---- ---- ---- ----


Revenue $ 530 $ 904 $ 730 $ 1,799

Operating expenses 1,829 4,467 4,589 6,484

Provision for income tax -- -- -- --
------- ------- ------- -------

Net (loss) $(1,299) $(3,563) $(3,859) $(4,685)
======= ======= ======= =======

Net (loss) per share:
Basic and diluted $ (0.16) $ (0.44) $ (0.47) $ (0.59)
======= ======= ======= =======


Weighted average number
of common shares
outstanding:
Basic and diluted (000) 8,159 8,017 8,133 8,003


At January 31, At July 31,
2008 2007
---- ----
Other Financial Data
Cash and cash equivalents $ 4,522 $ 6,572
=========== ===========
Total assets $ 5,762 $ 9,713
=========== ===========

Total liabilities $ 2,161 $ 2,114
=========== ===========

Shareholders' equity $ 3,601 $ 7,599
=========== ===========

[lerchengrund]

Die beste ist immer noch die gleiche, die ich auch anwende: Einfach nach massiv unterbewerteten Aktien suchen und sich auf wirklich gesunde Unternehmen konzentrieren, die in Ihrem Kerngeschäft wachsen und ein gutes Management haben.

[married]

Antwort auf Beitrag Nr.: 33.819.941 von lerchengrund am 06.04.08 13:34:07

Nun, von den o.g. "40 Milliarden"

könnten diese erste 20 Millionen pro Jahr schon ein guter Anfang sein ( und dabei immer an die MKpt von CTT denken ! ):

Competitive Technologies Signs Letter of Agreement for European Distribution of Pain Management Device
Wednesday April 30, 8:50 am ET

FAIRFIELD, Conn., April 30, 2008 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT - News) announced today that is has signed a letter of agreement with a billion-dollar European healthcare company in anticipation of granting them European distribution rights for CTT's pain management therapy device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. It has Medical Device CE certification from the European Union allowing European sales.

ADVERTISEMENT
Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the device was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community(tm). The device, with a biophysical rather than a biochemical approach, uses single-use surface electrodes applied to the skin to simultaneously treat multiple pain areas. CTT has exclusive worldwide rights to the therapy device. CTT partner GEOMC Co., Ltd. of Korea, formerly Daeyang E&C, is producing the device commercially for worldwide distribution.

Prof. Valori stated, ``This agreement highlights and reinforces the strong technical, scientific and business relationship between the U.S. and Italy. In cooperation with the Zangani Investor Community, we have produced our first successful transaction, and are working together to commercialize additional business opportunities.''

CTT is working to obtain FDA 510(k) medical device authorization for U.S. sales, as well as seeking approval for sales in other countries. Revenue is expected to grow in succeeding years as global market penetration increases. CTT expects revenues to be approximately $20 million per year, as the device attains mature market levels. CTT will launch and demonstrate the device in the U.S. next week at the American Pain Society's 27th Annual Scientific Meeting in Tampa, FL.

``This important technology has been successfully used in seven hospitals in Italy on over 2,000 patients,'' said John B. Nano, CTT's Chairman, President and CEO. ``There are over 16,000 hospitals in addition to hospices and pain treatment centers throughout Europe that can utilize this pain treatment device. We are working to launch the sales program to these prospects. We believe that revenue and profits from the pain management technology will dramatically exceed those produced by any other technology in our 40-year history. There is exciting potential for its success in the global pain management market; a market estimated to reach $40 billion by 2010.''

The U.S. Department of Commerce estimates the world market for all medical products, excluding pharmaceuticals, at $248 billion. The United States represents about half that market, with Europe at $75 billion for a 30% share. The U.K., France, Germany and Italy are estimated to represent nearly 80% of the total European market.

Mr. Nano continued, ``This is another example of a CTT technology being at the forefront of the paradigm shift to treat individuals with integrative medicine, combining traditional and holistic medicine. CTT's management team is focused on creating value from technologies, restoring stockholder value by signing new license agreements. In addition to the pain management therapy, we are aggressively marketing the breast cancer detection test, MC Square stress reduction device ( http://www.relaxmc.com), solar panels, and UAD surgical prosthetics technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website

[lerchengrund]

Antwort auf Beitrag Nr.: 34.002.670 von married am 30.04.08 15:26:14

toll!

[aktienworker]

Antwort auf Beitrag Nr.: 34.002.670 von married am 30.04.08 15:26:14

bei 8,5 Mio. Euro oder 5,5 Mio. Dollar MKpt sollte noch genügend Platz
nach oben sein.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.006.566 von aktienworker am 30.04.08 21:36:03

Wenn Sie bei Ihren Aktienkäufen und -verkäufen den Einfluss von Emotionen ausschalten, haben Sie eine der Hauptfehlerquellen im Griff. Sie handeln besonnen und entlang einer klaren Linie. Die so genannten “Psychofallen„ spielen dann für Sie keine Rolle mehr.

[aktienworker]

Antwort auf Beitrag Nr.: 34.008.793 von lerchengrund am 01.05.08 12:24:04

was soll den das für eine Belehrung sein?
für mich ist das nur Chinesisch

[lerchengrund]

Antwort auf Beitrag Nr.: 34.011.827 von aktienworker am 01.05.08 22:29:03

nein deutsch!

[married]

.

1.400 gehandelte Stücke

Nicht auszudenken wie hier ein BID aussehen muß wenn sich die 20 Mio. konkretisieren.



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.021.269 von married am 03.05.08 12:36:01

DIE WELT-INFLATION STEIGT! Ein Grund sind die Knappheitspreise bei den Industrie-, Agrar- und Energie-Rohstoffen. Hinzu kommt die Geldflut: Ben Bernanke fördert bewusst die Geldentwertung und wahrscheinlich nicht nur für kurze Zeit. Die Europäische Zentralbank hält den Leitzins noch stabil, ist aber ebenfalls bereits mit Inflationsraten über 3% konfrontiert, die sie eigentlich nicht tolerieren möchte – jetzt aber tolerieren muss, um den Dollar nicht endgültig abschmieren zu lassen. Zudem sorgt sich auch China über Inflationsraten in der Nähe von 10%.

[married]

Zurück zur CTT.

Jetzt wollen wir doch ein Mal sehen was uns das APS Meeting Ende der Woche an Aufmerksamkeit bringt.


Press Release Source: Competitive Technologies, Inc.


Competitive Technologies Files FDA Application for Pain Management Device
Monday May 5, 8:50 am ET
CTT to Display the Device At APS Meeting in Tampa


FAIRFIELD, Conn., May 5, 2008 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has applied for FDA 510(k) medical device authorization for U.S. sales of its pain management therapy device. The CTT device has Medical Device CE certification from the European Union allowing European sales for this non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. CTT has exclusive worldwide rights to this patented device.
CTT will launch and display the device in the U.S. at the American Pain Society's (APS) 27th Annual Scientific Meeting in Tampa, FL on May 8 and 9, 2008 (http://www.ampainsoc.org). The APS is a multidisciplinary community that brings together scientists, clinicians and other professionals to increase the knowledge of pain and transform public policy and clinical practice to reduce pain-related suffering.

ADVERTISEMENT


``The application to the FDA is CTT's next step in the global commercialization of this amazing device,'' said Aris D. Despo, CTT's Executive VP, Business Development. ``This device offers relief to patients suffering extreme pain. We have high expectations for its use in the U.S. market. It has been used successfully on over 2,000 patients in seven hospitals in Europe. Upon FDA approval, our initial sales focus will be on hospitals, pain clinics, hospice centers and pain management specialists.''

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, DSc, MD, the device was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community(tm). It uses a multi-processor designed to create self-like neurons by applying surface electrodes to the skin to simultaneously treat multiple pain areas. CTT partner, GEOMC Co. Ltd. of Korea, formerly Daeyang E&C, is producing the device commercially for worldwide distribution. GEOMC has invested about $1.3 million in design and tooling to produce the sleek, fully commercial product. A senior executive from GEOMC will be attending this meeting of over 3,000 delegates with CTT.

``We are proud to present this innovative technology to this gathering of pain management officials,'' said John B. Nano, CTT's Chairman, President and CEO. ``This device targets the American Pain Society's goal of reducing pain related suffering. CTT's objective is to commercialize this device worldwide. Based upon the European CE approval status, we have signed a letter of agreement with a billion-dollar European healthcare company for exclusive European distribution rights. We believe revenues from the device will dramatically exceed those produced by any other technology in our 40-year history, and reach approximately $20 million per year, as the device attains mature market levels.

``This is another example of a CTT technology fulfilling market needs. CTT's management team is focused on creating value from technologies, restoring stockholder value by signing new license agreements. In addition to the pain management therapy, we are aggressively marketing the breast cancer detection test, MC Square stress reduction device (http://www.relaxmc.com), solar panels, and UAD surgical prosthetics technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website.''

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: http://www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



Contact:
IR Services, LLC
Johnnie D. Johnson
860 434 2465
[e-mail]


--------------------------------------------------------------------------------
Source: Competitive Technologies, Inc.

http://biz.yahoo.com/pz/080505/141812.html

[lerchengrund]

Antwort auf Beitrag Nr.: 34.030.582 von married am 05.05.08 18:07:10

gibt es morgen was zu feiern?

[married]

Antwort auf Beitrag Nr.: 34.033.235 von lerchengrund am 05.05.08 23:53:44

.

Erwartest du das ?

.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.033.572 von married am 06.05.08 07:10:55

ja, ich warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte und warte ..................

[aktienworker]

Antwort auf Beitrag Nr.: 34.037.677 von lerchengrund am 06.05.08 15:26:30

Lieber Herr oder Frau Lerchengrund oder was auch immer.

Bis jetzt ist das was Sie schreiben und wie Sie es schreiben, ....
ach mir fehlen die Worte.

Ausser, bitte eröffnen Sie eigene Threads, wo jeder selber entscheiden
kann,mit Ihnen überhaupt die Meinungen auszutauschen.

[married]

Antwort auf Beitrag Nr.: 34.041.245 von aktienworker am 06.05.08 21:08:54

.



Dabei hat sein Warten doch ein Ende:



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.041.295 von married am 06.05.08 21:16:10

wo sind die news dazu?

[lerchengrund]

Antwort auf Beitrag Nr.: 34.041.295 von married am 06.05.08 21:16:10

oder ist der chart ein fake?

[married]

Antwort auf Beitrag Nr.: 34.041.488 von lerchengrund am 06.05.08 21:34:52

.

Hier gerne die url für den chart:

http://de.advfn.com/p.php?pid=staticchart&s=A^CTT&p=0&t=1&dm…

.

[aktienworker]

Antwort auf Beitrag Nr.: 34.041.911 von married am 06.05.08 22:17:53

Hinweis für Lerchengrund::O

Das Chaten ist für Kinder, hier nicht geeignet.
Aber zum Trost eine geeignete Webseite für Dich.

www.märchenerzähler.com

[aktienworker]

Antwort auf Beitrag Nr.: 34.041.245 von aktienworker am 06.05.08 21:08:54

Ach ja noch was, die gleiche ......von Dir bei YMI zu lesen.....

[married]

.

Interessant und als positives Indiz zu werten auch die verhältnismäßig vielen Insiderkäufe in den letzten 4 Wochen:

P 2008-04-24 2008-04-24 17:01:43 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 1,000 $1.41 $1,410.00 14,000 view
P 2008-04-23 2008-04-23 17:41:20 COMPETITIVE TECHNOLOGIES INC CTT Reali William L director 2,000 $1.35 $2,700.00 10,500 view
P 2008-04-23 2008-04-23 12:05:03 COMPETITIVE TECHNOLOGIES INC CTT Reali William L director 2,000 $1.35 $2,700.00 8,000 view
P 2008-04-21 2008-04-21 15:41:40 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 2,000 $1.21 $2,420.00 13,000 view
P 2008-04-16 2008-04-21 11:28:26 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 1,000 $1.15 $1,150.00 11,000 view
P 2008-04-15 2008-04-21 11:26:45 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 1,000 $1.20 $1,200.00 10,000 view
P 2008-04-11 2008-04-21 11:25:20 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 700 $1.21 $847.00 8,800 view
P 2008-04-14 2008-04-21 11:25:20 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 200 $1.21 $242.00 9,000 view

.

[married]

.



Eine kurze Konsolidierung wäre nicht ungesund nach diesem Verlauf:



.

heute wieder:



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.049.338 von married am 07.05.08 19:07:12

Das ist ne fette fette PARTY !

[married]

Ganz ohne comment:

Interessante Ansichten aus dem yahoo b.

Re: What will $20 million per year do for Stock Price?

30-Apr-08 11:47 pm That's 20 million with no cost of goods and tax loss carry forwards to shelter the income. That would be 2.00 a share in earnings (if you take out 4 million for overhead) until they have to pay tax. Pick your PE. 10 PE equals $20,
20 PE equals $40. etc. Maybe CTT will see 20 again. We can only hope



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.050.383 von married am 07.05.08 21:18:11

we hope and see !

[married]

Antwort auf Beitrag Nr.: 34.050.036 von lerchengrund am 07.05.08 20:38:51

.

Stimmt.

Und diese Party könnte im / bis zum Juni weitergehen:

The company has 3 investor meetings set up for the West Cost in June if any one is interested.





.




.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.060.300 von married am 08.05.08 22:21:40

alter schwede!

[married]

Antwort auf Beitrag Nr.: 34.068.861 von lerchengrund am 09.05.08 22:08:13

.

Nach starken 10 Tagen hat sie endlich ein Mal etwas gebremst / sich wie eine " normale Aktie benommen ".

Alles andere wäre ungesund.

Schöne Pfingsten !



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.068.914 von married am 09.05.08 22:16:15

Ein klares Kalkül hat immer etwas Bestechendes. Natürlich habe ich auch schon unter der Börsenpsychologie gelitten! Kein Zweifel - da ruinieren automatische Verkaufsprogramme und Ausverkaufsaktionen von Fondsmanagern die Kurse von exzellenten Unternehmen, dass man es mit dem Verstand gar nicht mehr fassen kann...
Und dass man sich rückblickend die Haare raufen möchte und nur noch denkt, ach hätte ich doch damals zugeschlagen, dann ging’s mir heute besser...
Kurzfristig herrscht immer ein hoch emotionales Kursgewoge, das an den Nerven reibt. Doch genau das ist das Schöne an der Börse - irrationale Kurse sind oft die größten Chancen überhaupt.
Denn die bequemsten Gewinne machen wir dort, wo wir exzellente Unternehmen abstauben können, die wir sowieso schon auf der Beobachtungsliste haben.

[married]

.





John Nano - CTT - will be presenting on Thursday May 22nd in Rome:


http://www.zangani.com/files/conference/pf2008/schedule.pdf

.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.136.281 von married am 20.05.08 19:17:52

Das charttechnische Bild hat sich im kurzfristigen Bereich zwar eingetrübt, aber noch ist nichts verloren. Es ist durchaus normal, dass es an solchen Marken zu Kämpfen zwischen Bullen und Bären kommt. Gerade hier werden gerne Fehlsignale generiert, so dass man diese Signale nicht überbewerten darf.
Trotzdem sollten wir nun höchste Vorsicht walten lassen und uns auf eine Konsolidierung einstellen, ohne jedoch in Panik zu geraten.
Noch sind die fundamentalen Grundvoraussetzungen bullish, noch müssen wir lediglich davon ausgehen, dass es eine normale Konsolidierung in einem Aufwärtstrend ist. Ob sich dieses Bild aber ändert, wird erst in den nächsten Tagen / Wochen entschieden.

[married]

Antwort auf Beitrag Nr.: 34.137.330 von lerchengrund am 20.05.08 21:15:48

.

Noch sind die fundamentalen Grundvoraussetzungen bullish

Welche meinst du da genau ?

.

[married]

Antwort auf Beitrag Nr.: 34.137.330 von lerchengrund am 20.05.08 21:15:48

.

Heute (k)eine Meinung ?

Vor rund 4 Wochen noch bei 1.17 ... :




.

[married]

Antwort auf Beitrag Nr.: 34.146.888 von married am 21.05.08 21:51:44

.

Und zum Schluss:

Time Ex Price Change Volume

16:00:16 Z 3.30 +0.36 4,000

15:57:27 Z 3.15 +0.21 200

15:55:20 Z 3.20 +0.26 100

15:53:28 Z 3.17 +0.23 100

15:53:28 Z 3.16 +0.22 200

15:48:12 Z 3.15 +0.21 100

15:48:12 Z 3.1899 +0.2499 1,000

15:45:12 Z 3.20 +0.26 800

15:45:12 Z 3.20 +0.26 200

15:43:41 Z 3.15 +0.21 1,000

.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.147.157 von married am 21.05.08 22:25:27

ist das die passende Nachricht? :


University of Connecticut Health Center and Competitive Technologies Announce NIH Grant for Asthma Study
FARMINGTON, Conn. and FAIRFIELD, Conn., May 19, 2008 (PRIME NEWSWIRE) -- University of Connecticut Health Center and Competitive Technologies, Inc. (AMEX:CTT) announced today that Dr. Eric Secor Jr., assistant professor from the Department of Immunology at the University's School of Medicine in Farmington, has been awarded a multiyear $750,000 K-08 Career Development Award from the National Institutes of Health (NIH) and the National Center of Complementary and Alternative Medicine (NCCAM). Dr. Secor's grant is a continuing study of anti-inflammatory and immunomodulatory effects of bromelain, a natural botanical product, in asthma. This work has originated in association with Dr. Roger Thrall, a prominent asthma researcher and recipient of several NIH grants including his current $1.8 million grant to investigate the mechanisms of allergic asthma. CTT has been providing basic funding for Dr. Secor's research to support his proposal to the NIH.


"The University is extremely pleased with receipt of this NIH grant," said Michael J. Hogan, President of the University of Connecticut. "As the state's premier public research university, we sponsor cutting-edge research that generates innovation, academic advancement, economic growth, and improves the lives of our citizens for generations to come. Dr. Secor's grant represents an ideal cooperation between the University, business and government."

CTT is working with Dr. Secor to develop diagnostic tests for asthma and to determine the applicability of bromelain as a treatment. Dr. Secor's NIH grant states that botanicals with unknown mechanisms of action are widely used for treatment and management of acute and chronic conditions such as allergy and asthma. His study of the effect of botanicals and their extracts on the immune system will help clarify the anti-inflammatory mechanism(s) of action of bromelain. Highlighting the global scope of this field, Dr. Secor gave a presentation on his research at the European Traditional Medicine International Congress held in Vinci, Italy, in October 2007, and he will present this month in Toronto, Ontario.

Dr. Secor stated, "Our laboratory work has demonstrated that bromelain affects inflammatory CD4+ T cells which are vital in immune responses in conditions such as allergy and asthma. These continued studies are crucial to understanding the mechanisms, which are responsible for the anti-allergy effects of botanicals such as bromelain. We look forward to our NIH funded work undergoing the peer review process and being published in the appropriate scientific journals."

"The K-08 Award is extremely prestigious grant and supports our confidence in the importance of the research being conducted by Drs. Secor and Thrall," said Ted Kutrumbos, Business Development Consultant for CTT. "It is another example of our being at the forefront of the paradigm shift to treat individuals with integrative medicine, which combines cutting edge science with traditional medicine."

Asthma, a chronic disease that affects breathing, cannot be cured but can usually be controlled. According to the NIH, asthma affects an estimated 22 million people in the U.S., including about six million children. About half of those affected suffer from allergic asthma.

"We look forward to continuing our work with Dr. Secor," said John B. Nano, CTT's Chairman, President and CEO. "CTT's management team is focused on creating value from technologies, restoring stockholder value by signing new license agreements. We are aggressively marketing the pain management therapy, breast cancer detection test, MC Square stress reduction device (www.relaxmc.com), and solar panel technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website."

About the University of Connecticut Health Center

The University of Connecticut Health Center includes the schools of medicine and dental medicine, the UConn Medical Group, University Dentists, and John Dempsey Hospital. Founded in 1961, the Health Center pursues a mission of providing outstanding health care education in an environment of exemplary patient care, research and public service. To learn more about the UConn Health Center, visit our website at http://www.uchc.edu.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

CONTACT: IR Services, LLC
Johnnie D. Johnson
860 434 2465
[e-mail]

[married]

Antwort auf Beitrag Nr.: 34.147.198 von lerchengrund am 21.05.08 22:32:39

.

Eher schon solche wie diese:

Press Release Source: Competitive Technologies, Inc.


Competitive Technologies Provides Pain Therapy Device to Major Cancer Hospice Center

Thursday May 22, 8:50 am ET


FAIRFIELD, Conn., May 22, 2008 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has provided a pain therapy device to the major cancer hospice center, The Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST). John B. Nano, CTT's Chairman, President and CEO and Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A made the presentation in a ceremony today Thursday, May 22, 2008 in Rome. The device was presented during the Gala Dinner of Pharma Finance 2008 sponsored by the Zangani Investor Community(tm). Prof. Valori highlighted how this pain device known as a ``merciful machine'' will assist terminally ill patients, providing a dignified end of life. The device will be used for pain therapy and for demonstration during the training of staff of other health care centers.
ADVERTISEMENT


CTT has exclusive worldwide distribution rights to its pain therapy device, a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The CTT device has Medical Device CE certification from the European Union allowing European sales and CTT has applied for FDA 510(k) medical device authorization for U.S. sales of the device. The patented device uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin.

``There is no event worse than observing any human being suffer from pain such as from cancer, especially pain that is drug resistant,'' said Mr. Nano. ``We believe there is no other product like ours on the market anywhere in the world today that can successfully treat high intensity oncologic pain resistant to morphine and other drugs.''

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, DSc, MD, the device was brought to CTT through the efforts of Prof. Valori, and assistance from the Zangani Investor Community(tm). CTT partner, GEOMC Co. Ltd. of Korea, formerly Daeyang E&C, is producing the device commercially for worldwide distribution.

``CTT's objective is to commercialize this device worldwide,'' said Mr. Nano. ``Based upon the European CE approval status, we have signed a letter of agreement with a multi-billion-dollar European healthcare company for exclusive European distribution rights. We believe revenues from the device will dramatically exceed those produced by any other technology in our 40-year history, and reach approximately $20 million per year, as the device attains mature market levels.''

About The Scientific Institute of Romagna for the Study and Treatment of Cancer

IRST is a Limited Liability Partnership that forms the core of the integrated oncological network in the Rome Regional Health Care System and provides governance for oncological research in the Region. It provides primary health care for the Forli territory and is an oncological center for secondary and tertiary health care for the whole of the Rome area. Its main aims are to reorganize and rationalize the care and treatment of cancer, to introduce a new organizational and management solution allowing the public and private sectors to work together, and to define and improve the standards of oncological research.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: http://www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



Contact:
IR Services, LLC
Johnnie D. Johnson
860 434 2465
[e-mail]


--------------------------------------------------------------------------------
Source: Competitive Technologies, Inc.

[married]

.

Der newsflow scheint auch im Kurs widerzuspiegeln, will heißen von den Investoren weiterhin mit getragen zu werden:



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.154.297 von married am 22.05.08 20:30:59

CTT has exclusive worldwide distribution rights to its pain therapy device, a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The CTT device has Medical Device CE certification from the European Union allowing European sales and CTT has applied for FDA 510(k) medical device authorization for U.S. sales of the device. The patented device uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin.

``There is no event worse than observing any human being suffer from pain such as from cancer, especially pain that is drug resistant,'' said Mr. Nano. ``We believe there is no other product like ours on the market anywhere in the world today that can successfully treat high intensity oncologic pain resistant to morphine and other drugs.''

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, DSc, MD, the device was brought to CTT through the efforts of Prof. Valori, and assistance from the Zangani Investor Community(tm). CTT partner, GEOMC Co. Ltd. of Korea, formerly Daeyang E&C, is producing the device commercially for worldwide distribution.

``CTT's objective is to commercialize this device worldwide,'' said Mr. Nano. ``Based upon the European CE approval status, we have signed a letter of agreement with a multi-billion-dollar European healthcare company for exclusive European distribution rights.

[married]

Antwort auf Beitrag Nr.: 34.154.579 von lerchengrund am 22.05.08 21:07:13

.

Nach dem Anstieg der letzten Wochen heißt es nun ausatmen vor den nächsten events. Es geht dort vorrangig darum diesen " Gemischtwarenladen im Technologietransfer " mit einer derzeitigen Marktkapitalisierung von lächerlichen 25 Mio. Dollar einer breiteren Masse an Investoren bekannt zu machen. Wenn dazu auch noch ein paar weitere news gereicht werden kann es uns nur recht sein.



SAN DIEGO

Thursday, June 19th, 1:15 pm
The University Club
750 B Street


NEWPORT BEACH

Friday, June 20th, 1:15 pm
The Daily Grill (Fashion Island)
957 Newport Center Drive


SAN FRANCISCO

Wednesday, June 25th, 1:15 pm
Le Meridien Hotel
333 Battery Street



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.211.340 von married am 31.05.08 20:57:29

wenn bald mal eine ordentliche dividende gezahlt werden sollte !? - spätestens dann spricht sich es rum.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.211.340 von married am 31.05.08 20:57:29

[married]

Antwort auf Beitrag Nr.: 34.211.791 von lerchengrund am 01.06.08 00:39:06

.

Press Release Source: Competitive Technologies, Inc.


Competitive Technologies Reports Third Quarter Fiscal 2008 Results
Thursday June 12, 8:50 am ET


FAIRFIELD, Conn., June 12, 2008 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT - News) today announced financial results for the three and nine months ended April 30, 2008.


The financial results for the third quarter ended April 30, 2008 are a net loss of approximately $1.0 million, or $0.12 per share, a 50% reduction in the net loss when compared to the net loss of approximately $2.0 million, or $0.25 per share, for the prior year quarter. The net loss for the nine-month period ending April 30, 2008 is $4.9 million, or $0.60 per share, a 28% reduction in the net loss when compared to the net loss of $6.7 million, or $0.84 per share, for the prior-year period. Cash position at quarter end was $2.9 million, with no long-term debt.

``We have continued to reduce costs and believe revenue will grow as we progress with our sales program for the pain management device and other innovative technologies in our portfolio,'' said John B. Nano, CTT's Chairman, President and CEO. ``We have collected over $700,000 for our client and for CTT by successfully enforcing our homocysteine patent rights, collecting royalties due on the patent that expired in July 2007. Moving in the right direction toward restoring profitability, we reduced our cost base in the third quarter fiscal 2008 by 57% below the prior year quarter. In addition, our 40% staff reduction and other cost-cutting actions will lower future operating costs. We continue to market and build our technology portfolio to exploit the opportunities of the paradigm shift resulting from record high costs of both healthcare and energy.

``We predict strong near-term results for the pain management device that will be marketed globally. We proudly announced the NIH grant for Asthma study at the University of Connecticut's School of Medicine for research supported by CTT that we believe will rapidly lead to an Asthma assay. Also, we recently obtained rights to a compressed air drying device from SECO in Italy.

``Sales and profit prospects for our innovative pain management device, a significant component of our rapidly developing medical strategy, are highly encouraging. We believe revenues from the device will dramatically exceed those produced by any other technology in our 40-year history, and reach approximately $20 million per year, as the device attains mature market levels. A letter of agreement has been signed with a multi-billion-dollar European healthcare company for exclusive European distribution rights. The non-invasive treatment, with European Union Medical Device CE certification, has been successfully used in seven hospitals in Italy on over 2,000 individuals who suffer from drug-resistant pain, including pain from cancer, back pain, and cranial pain, as well as sciatic pain. An FDA application has been filed for 510(k) authorization for US sales. The device is being manufactured by CTT licensee GEOMC Co., Ltd. of Korea, formerly Daeyang E&C, for worldwide distribution.

``Several factors earlier in the year also contributed to CTT's improving picture. The settled arbitration with Palatin Technologies, Inc. allowed CTT to reclaim its proper rights to the important sexual dysfunction technology. Our expanded medical strategy includes a license to Percept BioSciences for development of a library of patented attention and cognitive enhancement compounds from our client, the Medical College of Georgia, and an agreement to represent Angioscan's non-invasive early-detection test for breast cancer. We also signed an agreement to represent NTRU in Korea for their suite of products for embedded security software solutions.''

Total revenues for the quarter ended April 30, 2008, were approximately $0.2 million, compared to approximately $0.9 million in the same period of the prior year. Revenues for the nine-month period ended April 30, 2008 were $1.0 million compared to $2.7 million in the same period of the prior year. The decrease in total revenues was primarily due to the decrease in retained royalties for homocysteine, partially offset by increased royalties for the sexual dysfunction technology. CTT is currently pursuing litigation against alleged infringers of the homocysteine patent.

Expenses for the quarter ended April 30, 2008 were approximately $1.2 million, a 57% decrease, compared to approximately $2.9 million in the prior year quarter. Expenses for the nine-month period ended April 30, 2008 were approximately $5.8 million, a 38% decrease, compared to $9.4 million for the prior year period.

Mr. Nano continued, ``CTT's management team is focused on creating profitable revenue growth from technologies, restoring shareholder value, building global alliances, and maximizing the dynamic opportunities of our technologies. We are aggressively marketing the pain management therapy, breast cancer detection test, MC Square stress reduction device (http://www.relaxmc.com), solar panels, and UAD surgical prosthetics technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website.''

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: http://www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



COMPETITIVE TECHNOLOGIES, INC.

FIRST NINE MONTHS FISCAL 2008

CONDENSED CONSOLIDATED RESULTS OF OPERATIONS
(dollars in thousands, except per share amounts) (unaudited)

Third Quarter Ended Nine Months Ended
April 30, April 30,
2008 2007 2008 2007
---- ---- ---- ----


Revenue $ 238 $ 892 $ 968 $ 2,692

Operating expenses 1,249 2,934 5,838 9,419

Provision for income tax -- -- -- --
------- ------- ------- -------

Net (loss) $(1,011) $(2,042) $(4,870) $(6,727)
======= ======= ======= =======

Net (loss) per share:
Basic and diluted $ (0.12) $ (0.25) $ (0.60) $ (0.84)
======= ======= ======= =======


Weighted average
number of common
shares outstanding:
Basic and diluted (000) 8,180 8,048 8,148 8,018




At April 30, At July 31,
2008 2007
---- ----
Other Financial Data
Cash and cash equivalents $ 2,901 $ 6,572
======= =======
Total assets $ 4,372 $ 9,713
======= =======

Total liabilities $ 1,733 $ 2,114
======= =======

Shareholders' equity $ 2,639 $ 7,599
======= =======




Contact:
IR Services, LLC
Johnnie D. Johnson
CT -- 860 434-2465
NY -- 212 848-0275
[e-mail]


--------------------------------------------------------------------------------
Source: Competitive Technologies, Inc.


http://biz.yahoo.com/pz/080612/144522.html

.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.292.735 von married am 12.06.08 20:39:16

# 50

[lerchengrund]

Antwort auf Beitrag Nr.: 34.292.735 von married am 12.06.08 20:39:16

das wird noch ein bischen dauern, bis der break-even point erreicht ist.

[married]

Antwort auf Beitrag Nr.: 34.293.897 von lerchengrund am 13.06.08 00:10:25

.



Hauptsache hier geht es wieder weiter:



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.300.584 von married am 13.06.08 20:56:45

ups, da hab' ich ja was verpasst: ab 19:15 gin es los.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.300.584 von married am 13.06.08 20:56:45

gibt es eine Meldung?

[lerchengrund]

Antwort auf Beitrag Nr.: 34.300.584 von married am 13.06.08 20:56:45

[married]

Antwort auf Beitrag Nr.: 34.305.302 von lerchengrund am 15.06.08 15:58:58

.

Nichts was wir nicht schon wußten, bzw. durch die Meldung unten nochmals verifiziert wurde.

Auch stehen nun bis zum 25. Juli insgesamt 3 Präsentationen an.

Press Release Source: Competitive Technologies, Inc.


Competitive Technologies to Display Pain Management Device At BIO International Convention
Friday June 13, 8:50 am ET


FAIRFIELD, Conn., June 13, 2008 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT - News) announced today that they will display their pain management therapy device at the BIO International Convention in San Diego, CA from June 17 - 20 (http://www.bio2008.org). The convention is the world's largest gathering of biotechnology, pharmaceutical, nanotechnology, and medical device leaders.
Source: Competitive Technologies, Inc.


· MC5A Pain Therapy Device
· Visit website




CTT has exclusive worldwide distribution rights to its pain therapy device, a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The CTT device has Medical Device CE certification from the European Union allowing European sales and CTT has applied for FDA 510(k) medical device authorization for U.S. sales of the device. The patented device uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin.

``We are proud to present this device, together with our full portfolio of innovative technologies, to this gathering of international biotech leaders,'' said John B. Nano, CTT's Chairman, President and CEO. ``One of the purposes of BIO is to help heal the world through innovation. We believe there is no other product like ours on the market anywhere in the world today that can successfully treat high intensity oncologic pain resistant to morphine and other drugs.''

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, DSc, MD, the device was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community(tm). CTT partner, GEOMC Co. Ltd. of Korea, formerly Daeyang E&C, is producing the device commercially for worldwide distribution.

``CTT's objective is to commercialize this device worldwide,'' said Mr. Nano. ``Based upon the European CE approval status, we have signed a letter of agreement with a multi-billion-dollar European healthcare company for exclusive European distribution rights. We believe revenues from the device will dramatically exceed those produced by any other technology in our 40-year history, and reach approximately $20 million per year, as the device attains mature market levels.

``CTT will feature several other technologies at the convention in addition to the pain management device. These include our melanocortins, nanotechnology bone biomaterial, antimicrobial peptides, UAD surgical prosthetic, and Lupus diagnostic and monitoring technologies. Our full technology portfolio may be viewed on our website.''

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: http://www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



Contact:
IR Services, LLC
Johnnie D. Johnson
860 434 2465
[e-mail]


--------------------------------------------------------------------------------
Source: Competitive Technologies, Inc.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.305.432 von married am 15.06.08 16:49:29

heute wird in Dtl. erst mal nachgezogen.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.309.039 von lerchengrund am 16.06.08 13:30:38

[married]

Antwort auf Beitrag Nr.: 34.319.915 von lerchengrund am 17.06.08 21:21:46

.

Dieser Monat sollte noch 1 - 2 Dollars bringen. Insgeheim hoffe ich sogar auf eine Übernahme durch einen Big Player ....

Zu deinem Chart, so sehe ich es noch lieber:



.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.321.082 von married am 18.06.08 07:43:24

in EURO gesehen, haben wir jetzt die 2 EUR Marke übersprungen und stehen jetzt bei 2,04

[married]

.

Sehr ruhig zur Zeit. Ich hatte mir nach den Veranstaltungen etwas mehr Nachfrage erwartet. Nun, der Gesamtmarkt regt eben auch nicht besonders stark zu Käufen an.

Insider scheinen aber erwartungsfroh zu bleiben:

Buy(P) /
Sell(S) P/S

date Filed Date Company Symbol Insider Relationship Share Amt. Unit Price Total Proceeds Shares Owned Return(1m)


P 2008-06-20 2008-06-24 09:06:05 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 500 $3.01 $1,505.00 14,500

P 2008-06-23 2008-06-24 09:06:05 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 1,000 $2.84 $2,840.00 15,500

.

[married]

.

Und weiter abwärts auf nun 2.15 Dollar.

Der Investor kann nun mind. dreierlei Gedankenspiele in seine Entscheidung(en) einbringen:

1.) Der Kurs wird für eine ( feindliche ? ) Übernahme vorbereitet ( gedrückt )

2.) Bei den letzten 3 Präsentationen wurde keine oder nur weit unterhalb der Erwartungen liegende " Abschlüsse " getätigt.

3.) Zufallsbedingte Kurse, da Tagesumsätze unterdurchschnittlich ( bezogen auf die letzten Wochen )



.

[married]

.

Nun sind wir also wieder auf den " Optionsschein - Preis " von unter 2.00 Dollar zurückgekommen. Und so sollten dies ( wir )Investoren auch sehen. Also ein Call ohne ( vorerst ) feste Laufzeit, mit dem Risiko Totalverlust oder mit Kursen von 10.00 , 20.00 oder bis 100.00 Dollar.

Ein US - Boardler aus dem Yahoo-Board beschreibt die jetzige Situation so:

This is all about future earnings. And pain management is the best bet for future revs, let's see what deals they can deliver, there are several large players very interested in the technology. I expect an FDA approval this month for usage in the US. I'm sure we'll get some deals,(keep in mind we're talking about world wide distribution, one deal in just one major country is all we need) the question is how big, how long and how many? If Nano is right and we do 20 million in revs we are easily a 20 dollar stock. If he's wrong and we do only 10 million than we're a 10 dollar stock, if we do 100 million we're a 100 dollar stock. I like the risk /reward at $2.00

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.444.431 von married am 05.07.08 16:55:05

Zur Zeit lasten viele negative Faktoren auf der Börse.